AbCellera Reports Q3 2026 Business Results investors.abcellera.com/news/news-releases/2026/AbCellera…
AbCellera
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. More on Wikipedia
-
AbCellera
@AbCelleraBio
-
AbCellera
@AbCelleraBio
AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026 investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Present at Upcoming Investor Conferences in November 2026 investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
Visit our poster at The Menopause Society 2026 Annual Meeting. We will be presenting Phase 1/2 results on ABCL635, an investigational, potential best-in-class antibody drug for the non-hormonal treatment of vasomotor symptoms.
Read more about ABCL635 here: -
AbCellera
@AbCelleraBio
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
Attend our talk at IMS 2026 to see top-line Phase 2 results on ABCL635, an investigational, potential best-in-class antibody drug for the non-hormonal treatment of vasomotor symptoms.
Read more about ABCL635 here:
www.abcellera.com/pipeline/abcl635
#imsrio2026 #ims2026 -
AbCellera
@AbCelleraBio
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026 investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Reports Q2 2026 Business Results investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Appoints Dr. Lynn Seely to its Board of Directors investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies investors.abcellera.com/news/news-releases/2026/Jazz-Phar…
-
AbCellera
@AbCelleraBio
AbCellera Appoints Dr. Victor Sandor to its Board of Directors investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635 investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Present at Upcoming Investor Conferences in May and June 2026 investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026 investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Reports Full Year 2025 Business Results investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Present at Upcoming Investor Conferences in March and April 2026 investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
investors.abcellera.com/news/news-releases/2026/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause investors.abcellera.com/news/news-releases/2026/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera and Bruker Reach Global Settlement of Patent Litigation investors.abcellera.com/news/news-releases/2025/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 investors.abcellera.com/news/news-releases/2025/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Appoints Dr. Stephen Quake to its Board of Directors investors.abcellera.com/news/news-releases/2025/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Reports Q3 2025 Business Results investors.abcellera.com/news/news-releases/2025/AbCellera…
-
AbCellera
@AbCelleraBio
Visit our poster at ACoP 2025 Conference to learn how using Quantitative Systems Pharmacology (QSP) models can help predict and explain the diverse in vivo efficacy outcomes of T-cell engagers.
Read more about our TCE platform:www.abcellera.com/platform
#pharmacometrics #isop #acop -
AbCellera
@AbCelleraBio
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
www.abcellera.com/news/abcellera-to-participate-at-upcomi… -
AbCellera
@AbCelleraBio
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
www.abcellera.com/news/abcellera-to-report-third-quarter-… -
AbCellera
@AbCelleraBio
Visit our poster at #discoveryontarget in Boston to learn how our multiple T-cell engager (TCE) building blocks can be leveraged to tailor TCE design for diverse tumor targets.
Read more about our TCE platform:
www.abcellera.com/platform -
AbCellera
@AbCelleraBio
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
www.abcellera.com/news/abcellera-appoints-dr-sarah-noonbe… -
AbCellera
@AbCelleraBio
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera to Participate at Upcoming Investor Conferences in September
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
Visit our poster at Antibody Engineering & Therapeutics Europe 2025 to learn how we leverage multiple T-cell engager building blocks to generate molecules with in vivo efficacy.
Read more about our TCE platform: www.abcellera.com/publications?case_studies_tag=t-cell-en…
#antibodyengineering -
AbCellera
@AbCelleraBio
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
www.abcellera.com/news/abcellera-receives-authorization-f… -
AbCellera
@AbCelleraBio
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Reports Q1 2025 Business Results
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
Visit our poster at #pegssummit to learn how multiple T-cell engager (TCE) building blocks can be leveraged to tailor TCE design for diverse tumor targets.
Read more about our TCE platform: www.abcellera.com/publications?case_studies_tag=t-cell-en… -
AbCellera
@AbCelleraBio
Visit our poster at #sidsandiego25 to learn about a novel, fully human and half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis.
Read more about our pipeline here: www.abcellera.com/publications -
AbCellera
@AbCelleraBio
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
Visit our poster at #aacr25 to see how combining diverse CD3- and tumor-binding antibodies and empirically testing for optimal combinations can generate T-cell engagers (TCEs) with in vivo efficacy.
Read more about our TCE platform here: www.abcellera.com/publications?case_studies_tag=t-cell-en…
#immunooncology -
AbCellera
@AbCelleraBio
Visit our poster at #festivalofbiologics in San Diego to learn how we’re leveraging our T-cell engager (TCE) platform to design and optimize TCEs for solid tumor targets.
Read more about our TCE platform: www.abcellera.com/publications?case_studies_tag=t-cell-en… -
AbCellera
@AbCelleraBio
AbCellera to Participate at Upcoming Investor Conferences in May and June
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Reports Full Year 2024 Business Results
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera to Participate at Upcoming Investor Conferences in March
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Expands Collaboration with @abbvie to Develop Novel T-Cell Engagers for Oncology
investors.abcellera.com/news/news-releases/2025/AbCellera… -
AbCellera
@AbCelleraBio
Visit our poster at AET US to explore how tailored T-cell engager design strategies can be leveraged to widen the therapeutic window, and enhance efficacy.
#antibodyeng -
AbCellera
@AbCelleraBio
AbCellera to Present at Upcoming Investor Conferences in December and January
investors.abcellera.com/news/news-releases/2024/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
investors.abcellera.com/news/news-releases/2024/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Reports Q3 2024 Business Results
www.abcellera.com/news/abcellera-reports-q3-2024-business… -
AbCellera
@AbCelleraBio
GPCRs hold immense promise as therapeutic targets, but their complexity has posed significant challenges for traditional antibody development. Visit our poster at #pegseurope to see how we generated and optimized multiple high-quality antibodies against a GPCR target.
#antibodies -
AbCellera
@AbCelleraBio
Bringing effective TCEs to patients with difficult-to-treat cancers requires tailored design strategies. Visit our poster at SITC to learn how diverse building blocks can be leveraged to widen the therapeutic window and enhance efficacy.
abcellera.com/post/sitc2024/ -
AbCellera
@AbCelleraBio
AbCellera to Present at Upcoming Investor Conferences in November investors.abcellera.com/news/news-releases/2024/AbCellera…
-
AbCellera
@AbCelleraBio
Learn about how novel CD3-binding antibodies could widen the therapeutic window for T-cell engagers by visiting our poster at Festival of Biologics in Basel.
#festivalofbiologics #fob2024 #tcellengangers #cancer -
AbCellera
@AbCelleraBio
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
investors.abcellera.com/news/news-releases/2024/AbCellera… -
AbCellera
@AbCelleraBio
We’re excited to announce the publication of our review article in mAbs.
Read the review here: www.tandfonline.com/doi/full/10.1080/19420862.2024.2394229 -
AbCellera
@AbCelleraBio
GPCRs are high-value targets that have been largely intractable to conventional antibody discovery technologies. Visit our poster at Discovery on Target to see how we generated and optimized multiple high-quality antibodies against a GPCR.
#bostondot24 #drugtarget -
AbCellera
@AbCelleraBio
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
investors.abcellera.com/news/news-releases/2024/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera to Present at Upcoming Investor Conferences in September investors.abcellera.com/news/news-releases/2024/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Reports Q2 2024 Business Results investors.abcellera.com/news/news-releases/2024/AbCellera…
-
AbCellera
@AbCelleraBio
Learn about designing T-cell engagers (TCEs) with highly potent tumor-cell killing and reduced cytokine release. Visit our poster at #iosummit 2024 to find out more.
-
AbCellera
@AbCelleraBio
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines investors.abcellera.com/news/news-releases/2024/AbCellera…
-
AbCellera
@AbCelleraBio
Congratulations to our partner, @invetx , on its acquisition by Dechra Pharmaceuticals, a global leader in animal health.
www.invetx.com/invetx-announces-upcoming-acquisition-by-d… -
AbCellera
@AbCelleraBio
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
investors.abcellera.com/news/news-releases/2024/AbCellera… -
AbCellera
@AbCelleraBio
Learn about how to widen the therapeutic window for T-cell engagers using platform technologies. See our CD3 x PSMA case study at Antibody Engineering & Therapeutics #aeteu
-
AbCellera
@AbCelleraBio
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
investors.abcellera.com/news/news-releases/2024/AbCellera… -
AbCellera
@AbCelleraBio
Congratulations to our partner, @AbderaTx, on receiving FDA clearance for its IND application for ABD-147, an antibody-based precision radiotherapeutic targeting small cell lung cancer and large cell neuroendocrine carcinoma. abderatx.com/press-releases/abdera-therapeutics-announces…
-
AbCellera
@AbCelleraBio
Congratulations to @ArsenalBio , who in April announced the start of Phase 1/2 for AB-2100 in renal cell carcinoma.
arsenalbio.com/2024/04/30/arsenal-biosciences-announces-f… -
AbCellera
@AbCelleraBio
See us at #pegsboston to learn about our T cell engagers targeting prostate-specific membrane antigen (PSMA) that showed significantly lower cytokine release compared to clinical benchmarks.
-
AbCellera
@AbCelleraBio
AbCellera Reports Q1 2024 Business Results
investors.abcellera.com/news/news-releases/2024/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies investors.abcellera.com/news/news-releases/2024/AbCellera…
-
AbCellera
@AbCelleraBio
Congratulations to Andrew Booth, AbCellera's CFO, who is a recipient of @globeandmail's Report on Business 2024 Best Executive Awards.
Canada is at an inflection point. We have an opportunity to build, from the ground up, a life sciences ecosystem that will make our communities stronger, bring new medicines to patients, and create a legacy of innovation for generations to come. Thank you for leading us to today and paving the path for tomorrow.
www.theglobeandmail.com/business/rob-magazine/article-bes… -
AbCellera
@AbCelleraBio
There’s an opportunity to widen the therapeutic window of T-cell engagers by reducing cytokine release. See data on our CD3 x PSMA program at Festival of Biologics on April 15 - 17 to learn more. #fobusa
-
AbCellera
@AbCelleraBio
AbCellera presents data on T-cell engagers against four tumor targets at AACR 2024 investors.abcellera.com/news/news-releases/2024/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024 investors.abcellera.com/news/news-releases/2024/AbCellera…
-
AbCellera
@AbCelleraBio
See the latest data on T-cell engager programs for multiple tumor targets, including PSMA and challenging peptide-MHCs, at #aacr2024.
-
AbCellera
@AbCelleraBio
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024 investors.abcellera.com/news/news-releases/2024/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions investors.abcellera.com/news/news-releases/2024/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024 investors.abcellera.com/news/news-releases/2024/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Announces Resignation of Board Member investors.abcellera.com/news/news-releases/2024/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Present at Upcoming Investor Conferences in March investors.abcellera.com/news/news-releases/2024/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Reports Full Year 2023 Business Results investors.abcellera.com/news/news-releases/2024/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024 investors.abcellera.com/news/news-releases/2024/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 investors.abcellera.com/news/news-releases/2023/AbCellera…
-
AbCellera
@AbCelleraBio
Learn how to build optimal #bispecifics using innovative technologies. Join Patrick Farber at his talk at the upcoming AET conference in San Diego.
@AntibodyEngIC #antibodyengineering -
AbCellera
@AbCelleraBio
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
Learn how integrated technologies can efficiently generate antibodies that meet the TCP. Join Lucas Kraft at PEGS Europe.
-
AbCellera
@AbCelleraBio
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Reports Q3 2023 Business Results
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
investors.abcellera.com/news/news-releases/2023/Prelude-T… -
AbCellera
@AbCelleraBio
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
Integrate biomarker data early to advance #bispecifics to the clinic, faster.
Learn more by attending our talk with Raffi Tonikian at the World Bispecific Summit.
#antibodytherapeutics #antibodydiscovery -
AbCellera
@AbCelleraBio
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
Join AbCellera Co-Founder and COO Véronique Lecault and UBC VP Research & Innovation Gail Murphy on Sep 28 at 9:00a PT as they discuss entrepreneurship and some of the biggest challenges in human health @ubcentrepreneur #eiw23
Register today: innovation.ubc.ca/latest-updates/immersion-week-2023 -
AbCellera
@AbCelleraBio
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Reports Q2 2023 Business Results
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
Together with the Governments of Canada and British Columbia, AbCellera is co-investing to advance drug development capabilities and infrastructure that will bring new medicines to patients, create jobs, and fuel innovation. Read the full press release:
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
"Having the ability to not only create, but also produce our own medicines is really important for a nation. There are many win-win elements that the life sciences industry can bring to Canada’s future," said our COO and co-founder, Véronique Lecault.
thefutureeconomy.ca/interviews/pandemic-response-network-… -
AbCellera
@AbCelleraBio
Mark Fogg, AbCellera's Director of Partnering, will be presenting a poster on how to custom-build optimal #tcellengagers for diverse tumor targets with differentiated #cd3-binding #antibodies at #iosummituk.
Connect with us by visiting our poster from June 21 - 22. -
AbCellera
@AbCelleraBio
Join our Founder and CEO Carl Hansen as he chats with experts in the field about accelerating #drugdevelopment at the @LongwoodLeaders Spring 2023 MIT Conference.
#longwoodhealthcareleaders
www.longwoodhealthcareleaders.com/spring2023 -
AbCellera
@AbCelleraBio
Katherine Vousden will be presenting our poster on how to custom-build optimal T-cell engagers for diverse tumor targets with differentiated CD3-binding antibodies at Antibody Engineering and Therapeutics Europe. Connect with us by visiting our poster on June 6 at 5:45pm CEST.
#antibodyeng #tcellengagers #biologics #antibodydiscovery @AntibodyEngIC -
AbCellera
@AbCelleraBio
AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
Develop new #tcellengagers faster by combining a diverse, developable, and validated panel of CD3-binding #antibodies with a clinically-validated #bispecific engineering platform.
Learn how at #pegs23 by attending our talk and poster presentation. -
AbCellera
@AbCelleraBio
AbCellera Reports Q1 2023 Business Results
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera’s CEO, Carl Hansen, will be speaking about how to streamline #tcell Engager development at the Sydney Antibody Therapeutics Conference. sydneyantibodytherapeutics.com.au
-
AbCellera
@AbCelleraBio
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
Get from target to antibody development candidates with greater precision and speed. Learn how at Festival of Biologics by attending our talk, poster presentation, or by booking a meeting. www.abcellera.com/conference-festival-of-biologics-2023-p…
#festofbiologics #antibodydiscovery #biologics -
AbCellera
@AbCelleraBio
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera’s VP of Business Development, Anne Stevens, will be on a panel at #fiercebdlsummit. Tune in to learn about strategies for negotiating and evaluating platform deals, including identifying trends, new technologies and win-win collaborations.
www.bdlsummit.com -
AbCellera
@AbCelleraBio
AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Reports Full Year 2022 Business Results
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
Develop new T-cell engagers faster by combining a diverse, developable, and validated panel of CD3-binding antibodies with a clinically-validated bispecific engineering platform. Learn more at @Keystonesymp’s Multispecific Immune Cell Engagers for Cancer Immunotherapy.
-
AbCellera
@AbCelleraBio
AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera to Report Full Year 2022 Business Results on February 21, 2023
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
We’re excited to announce that our team in Boston, previously known as TetraGenetics, is now AbCellera Boston. Together we’re tackling some of the most difficult challenges in antibody discovery to bring treatments to patients faster.
-
AbCellera
@AbCelleraBio
Our CFO Andrew Booth and VP, Communications Tiffany Chiu have been recognized among the top 25 healthcare technology leaders of Vancouver for 2022 by the Healthcare Technology Report.
Congratulations to them and all of the awardees!
thehealthcaretechnologyreport.com/the-top-25-healthcare-t… -
AbCellera
@AbCelleraBio
Join our Founder and CEO Carl Hansen as he chats with experts in the field about accelerating #drugdevelopment at the @LongwoodLeaders Pre-#jpm2023 Webconference.
www.longwoodhealthcareleaders.com/sfceo -
AbCellera
@AbCelleraBio
AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
investors.abcellera.com/news/news-releases/2023/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera and @abbvie Partner to Advance New Antibody Therapies
investors.abcellera.com/news/news-releases/2022/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases investors.abcellera.com/news/news-releases/2022/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera presents new data on T-cell engager platform at SITC 2022.
investors.abcellera.com/news/news-releases/2022/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Reports Q3 2022 Business Results
investors.abcellera.com/news/news-releases/2022/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera to Present at Upcoming Investor Conferences in November
investors.abcellera.com/news/news-releases/2022/AbCellera… -
AbCellera
@AbCelleraBio
Combine a diverse, developable, and validated panel of CD3-binding antibodies with a clinically validated #bispecific engineering platform to streamline T-cell engager development. See the data at #sitc22.
www.sitcancer.org/2022/abstracts/abstract-titles-publicat… -
AbCellera
@AbCelleraBio
AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development
investors.abcellera.com/news/news-releases/2022/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Reports Q3 2022 Business Results on November 8, 2022
investors.abcellera.com/news/news-releases/2022/AbCellera… -
AbCellera
@AbCelleraBio
Partner with AbCellera at #bioeurope from October 24-26 in Leipzig.
partneringone.informaconnect.com/event/725/profile/user/7… -
AbCellera
@AbCelleraBio
Thank you to @BIOTECanada and congratulations to all of the recipients of the Gold Leaf Awards, including @adMare_Bio, @inversago, and Dr. Thomas Madden, President & CEO of @AcuitasTx. We’re proud to contribute to the growth of Canadian biotech.
BIOTECanada
@BIOTECanada
Gold leaf award winner @AbCelleraBio - will be great to host you this evening at BIONATION in Ottawa. bwnews.pr/3foXKTm #bionation2022 #gbw2022
-
AbCellera
@AbCelleraBio
AbCellera to present data on T-cell engager platform at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting on November 11, 2022.
investors.abcellera.com/news/news-releases/2022/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
investors.abcellera.com/news/news-releases/2022/AbCellera… -
AbCellera
@AbCelleraBio
We have broken ground on Phase II of our state-of-the-art tech campus in Vancouver, BC. Thank you to our development partner, @BeedieBuilt, and everyone who worked to make this facility possible.
-
AbCellera
@AbCelleraBio
Thank you to @nlonberg for joining our AbCellera Speaker Series and teaching us about the field of cancer immunotherapies. Nils’ industry-changing vision for immunotherapeutics has had a profound influence on AbCellera’s work. We’re incredibly grateful for his time and expertise.
-
AbCellera
@AbCelleraBio
We are excited to welcome our team in Australia, previously known as Channel Bio, under the AbCellera brand. Together we’re tackling some of the most difficult challenges in antibody discovery to bring treatments to patients faster.
-
AbCellera
@AbCelleraBio
Thank you @StephenQuake for joining our AbCellera Speaker Series. We are inspired by your work on the @humancellatlas, philosophies on tech entrepreneurship and training innovators, and projections on the future of biotech.
-
AbCellera
@AbCelleraBio
AbCellera Reports Q2 2022 Business Results
investors.abcellera.com/news/news-releases/2022/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
investors.abcellera.com/news/news-releases/2022/AbCellera… -
AbCellera
@AbCelleraBio
Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies
investors.abcellera.com/news/news-releases/2022/Versant-V… -
AbCellera
@AbCelleraBio
AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022
investors.abcellera.com/news/news-releases/2022/AbCellera… -
AbCellera
@AbCelleraBio
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
investors.abcellera.com/news/news-releases/2022/Lilly-to-… -
AbCellera
@AbCelleraBio
There has been a chronic underinvestment in tech that accelerates drug discovery and reduces risk. So, we asked ourselves: can it be built better?
Join us at #bio2022 to learn how AbCellera is creating a better front end to antibody drug development.
www.bio.org/events/bio-international-convention/sessions/… -
AbCellera
@AbCelleraBio
Join the panel discussion on the nuances of doing platform transactions moderated by AbCellera’s CBO Neil Berkley at #bio2022
www.bio.org/events/bio-international-convention/sessions/… -
AbCellera
@AbCelleraBio
Meet with AbCellera at #bio2022 to discuss how our technology delivers lead antibody candidates with a higher probability of success, faster. login.partnering.bio.org/inova-business-platform/webclient/
-
AbCellera
@AbCelleraBio
.@CellReports publishes data on bebtelovimab, the second AbCellera-discovered COVID-19 antibody treatment. This potent antibody therapy for COVID-19 is effective against all currently known variants of concern, including Omicron and the BA.2 subvariant.
www.cell.com/cell-reports/fulltext/S2211-1247(22)00583-6 -
AbCellera
@AbCelleraBio
AbCellera Reports Q1 2022 Business Results
investors.abcellera.com/news/news-releases/2022/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration investors.abcellera.com/news/news-releases/2022/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022 investors.abcellera.com/news/news-releases/2022/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022 investors.abcellera.com/news/news-releases/2022/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Presents Data on T Cell Engager Platform at AACR 2022 investors.abcellera.com/news/news-releases/2022/AbCellera…
-
AbCellera
@AbCelleraBio
Combine a diverse, developable, and validated panel of CD3-binding antibodies with a clinically-validated #bispecific engineering platform to develop new T cell engagers for cancer. See the data at #aacr22.
www.abstractsonline.com/pp8/ -
AbCellera
@AbCelleraBio
Bispecific antibody programs fail too often. Join us at #fobusa to learn how integrated discovery, engineering, and computational technologies can move your #bispecifics to the clinic, faster.
learn.abcellera.com/enduring-solutions-to-the-evolving-co… -
AbCellera
@AbCelleraBio
The Peak has recognized our Co-founder and VP, Discovery, Kathleen Lisaingo, among their 2022 class of Emerging Leaders. Congrats Kathleen and all of the other leaders recognized for shaping Canada’s economy, culture, and society. @readthepeak readthepeak.com/lists/emerging-leaders-2022/c/startups-an…
-
AbCellera
@AbCelleraBio
AbCellera Reports Full Year 2021 Business Results investors.abcellera.com/news/news-releases/2022/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools investors.abcellera.com/news/news-releases/2022/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022 investors.abcellera.com/news/news-releases/2022/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
investors.abcellera.com/news/news-releases/2022/AbCellera… -
AbCellera
@AbCelleraBio
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments investors.abcellera.com/news/news-releases/2022/Lilly-to-…
-
AbCellera
@AbCelleraBio
AbCellera to Report Full Year 2021 Financial Results on February 24, 2022 investors.abcellera.com/news/news-releases/2022/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera and its collaborators released new preclinical data showing the pseudovirus neutralization status of its two monoclonal antibodies, bamlanivimab and bebtelovimab (also known as LY-CoV1404), against the Omicron variant.
www.abcellera.com/news/abcelleras-statement-on-the-neutra… -
AbCellera
@AbCelleraBio
Multipass membrane proteins can be hard-to-make and hard-to-hit. Find out how an integrated technology stack makes milligram amounts of protein and drives antibody variety at Antibody Engineering & Therapeutics US. @AntibodyEngIC
informaconnect.com/antibody-engineering-therapeutics/agen… -
AbCellera
@AbCelleraBio
AbCellera Announces Changes to Its Board of Directors
“I look forward to working with them to help them realize the enormous impact their approach can have on the industry and, ultimately, on patients around the world." - Dr. Andrew W. Lo
investors.abcellera.com/news/news-releases/2021/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12 investors.abcellera.com/news/news-releases/2021/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer investors.abcellera.com/news/news-releases/2021/AbCellera…
-
AbCellera reposted
uOttawa Science
@uOttawaScience
Véronique Lecault, co-founder @AbCelleraBio, is the recipient of the Excellence Award - Young graduate of the year 2021 from the Faculty of Science. Congratulations and thank you for inspiring future science graduates.
Read more: www.uottawa.ca/faculty-science/ -
AbCellera reposted
EY Canada
@EYCanada
And Canada’s EY Entrepreneur Of The Year 2021 is… [⚙️] Carl Hansen of @AbCelleraBio! 🥇 Congratulations, Carl! You are truly unstoppable.
#eycanada #eoycanada #unstoppables -
AbCellera
@AbCelleraBio
Thank you to @wearebctech for honoring us with the Company of the Year - Anchor at this year’s Technology Impact Awards! #2021tias #bctech
wearebctech.com/technology-impact-awards-2021/
BC Tech Association
@wearebctech
Congrats to @AbCelleraBio, our #2021tias winner for Company of the Year - Anchor, sponsored by @DeloitteCanada! 🎉 #bctech
AbCellera
@AbCelleraBio
Congratulations to all of the nominees who are building great tech companies in BC! @absolutecorp @CymaxGroup @wellhealth #2021tias
-
AbCellera
@AbCelleraBio
We’re proud to be ranked 30th on @DeloitteTMT’s #fast500 list of growing tech companies in North America! www.deloitte.com/us/en/Industries/tmt/content/fast500-win…
AbCellera
@AbCelleraBio
We are also 4th on @DeloitteTMT’s #fast50 list of growing tech companies in Canada! Congratulations to all the @Deloitte Canada Fast 50 companies: www.deloitte.com/ca/en/Industries.html?icid=nav2_fast50-w…
-
AbCellera
@AbCelleraBio
AbCellera Reports Q3 2021 Business Results investors.abcellera.com/news/news-releases/2021/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Announces Virtual Presentations at Investor Conferences in November investors.abcellera.com/news/news-releases/2021/AbCellera…
-
AbCellera
@AbCelleraBio
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19
investors.abcellera.com/news/news-releases/2021/Lilly-to-… -
AbCellera
@AbCelleraBio
AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021 investors.abcellera.com/news/news-releases/2021/AbCellera…
-
AbCellera reposted
Forbes
@Forbes
At the #under30summit, @AbCelleraBio CEO Carl Hansen tells @TheAlexKnapp how he created the first authorized antibody treatment for COVID-19 and became an overnight billionaire. #forbesunder30
This media couldn't be displayed. See it on the original post. -
AbCellera
@AbCelleraBio
We are honoured to announce AbCellera Founder & CEO Carl Hansen as 2021 @BloomBurton Award winner. Each year, Bloom Burton recognizes an individual who made the greatest contribution to our healthcare industry in the previous year.
x.com/bloomburton/status/1443925031453663257 -
AbCellera
@AbCelleraBio
Learn how the operating system for antibody discovery made it possible for two unique human antibody therapies against SARS-CoV-2 and its variants to enter clinical testing in one year. Join us for Discovery on Target. #bostondot21
learn.abcellera.com/discovery-on-target-2021/ -
AbCellera
@AbCelleraBio
AbCellera is 5th on the @globebusiness list of top growing Canadian companies in 2021. Read about how we’re growing our dedicated and passionate team of AbCellerites. www.theglobeandmail.com/business/rob-magazine/top-growing…
#topgrowing21
AbCellera
@AbCelleraBio
Like the idea of working together on tough problems that have a real-world impact? Learn about opportunities to grow with us! www.abcellera.com/careers
-
AbCellera
@AbCelleraBio
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies investors.abcellera.com/news/news-releases/2021/AbCellera…
-
AbCellera
@AbCelleraBio
Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19 investors.abcellera.com/news/news-releases/2021/Lilly-to-…
-
AbCellera
@AbCelleraBio
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19 investors.abcellera.com/news/news-releases/2021/Emergency…
-
AbCellera
@AbCelleraBio
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines investors.abcellera.com/news/news-releases/2021/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets investors.abcellera.com/news/news-releases/2021/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference investors.abcellera.com/news/news-releases/2021/AbCellera…
-
AbCellera
@AbCelleraBio
.@ASPRgov & @US_FDA resumed use and distribution of bamlanivimab and etesevimab together in all US states, territories, and jurisdictions.
www.phe.gov/emergency/events/COVID19/investigation-MCM/Ba… -
AbCellera
@AbCelleraBio
.@ASPRgov & @US_FDA resumed allowing use of bamlanivimab & etesevimab together in certain geographies where recent data show the combined frequency of variants resistant to bamlanivimab & etesevimab administered together is 5% or less.
www.phe.gov/emergency/events/COVID19/investigation-MCM/Ba… -
AbCellera reposted
Endpoints News
@endpts
Interested in antibody R&D? Endpoints News is hosting a free webinar this Thursday to take a deep look into the field. Join below.
webinars.endpts.com/after-the-pandemic-antibody-rd-remain… -
AbCellera
@AbCelleraBio
Last week, we welcomed Minister Ravi Kahlon (@KahlonRav) to showcase our growing community of passionate, ambitious, and inspired AbCellerites who are working across disciplines to solve the toughest problems in antibody drug discovery.
-
AbCellera
@AbCelleraBio
ICYMI: “Maybe what surprised me was the massive impact that that could have in such a short time.”
Our CEO Carl Hansen spoke on the #rbcdisruptors podcast about bringing therapies to patients, faster.
thoughtleadership.rbc.com/the-vancouver-biotech-company-o… -
AbCellera
@AbCelleraBio
AbCellera Reports Q2 2021 Business Results investors.abcellera.com/news/news-releases/2021/AbCellera…
-
AbCellera
@AbCelleraBio
We're proud to be recognized as the Life Sciences Company of the Year by @lifesciences_bc. Congratulations to all of the winners, whose drive and creativity contribute to BC’s strong life sciences community. lifesciencesbc.ca/lsbc-news/life-sciences-bc-announces-an…
-
AbCellera
@AbCelleraBio
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
investors.abcellera.com/news/news-releases/2021/EQRx-and-… -
AbCellera
@AbCelleraBio
Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-Beta Superfamily Member for the Treatment of Cancer
investors.abcellera.com/news/news-releases/2021/Tachyon-a… -
AbCellera
@AbCelleraBio
Honored to welcome Minister @FP_Champagne to AbCellera and to discuss our growing tech campus in Vancouver where we’re solving the toughest challenges in drug discovery to help bring treatments to patients faster.
François-Philippe Champagne (FPC) 🇨🇦
@FP_Champagne
Had the chance to visit @AbCelleraBio, a world-class Canadian company that’s using AI to develop antibody drugs to fight disease faster than ever before. AbCellera's growing at light speed, attracting the brightest minds & helping make sure we’re prepared for future pandemics.
-
AbCellera
@AbCelleraBio
It has been a year of incredible achievements for AbCellera! Our CEO Carl Hansen has been named an @EYCanada Entrepreneur Of The Year® 2021 Pacific winner. Kudos to the courageous entrepreneurs working hard to do things that have never been done before.
www.ey.com/en_ca/news/2021/07/seven-unstoppable-pacific-e… -
AbCellera
@AbCelleraBio
AbCellera Appoints Neil Berkley as Chief Business Officer investors.abcellera.com/news/news-releases/2021/AbCellera…
-
AbCellera
@AbCelleraBio
We’re expanding our capabilities to include internal CMC development and #gmp manufacturing of antibodies to bring therapies from idea to patients, faster.
This life-changing work needs a world-class team of visionaries to make it happen.
Join us!
www.abcellera.com/careers/openings -
AbCellera
@AbCelleraBio
AbCellera continues expansion and strengthens future pandemic preparedness by building a first-of-its-kind Canadian GMP manufacturing facility, which will support our partners' clinical development of antibody therapies for an array of medical conditions. investors.abcellera.com/news/news-releases/2021/AbCellera…
-
AbCellera
@AbCelleraBio
Thank you to @AdamMGrant and Véronique Lecault for talking with the entire AbCellera team about confident humility, escalation of commitment, and thinking again. AbCellera inspires a culture of "givers". #thinkagain
-
AbCellera
@AbCelleraBio
Join our Cofounder and COO, Véronique Lecault, at #marsimpacthealth on June 22 to hear about how AbCellera and other health companies are building and scaling in Canada. @MaRSDD impacthealth.marsdd.com/program/
-
AbCellera
@AbCelleraBio
AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares
investors.abcellera.com/news/news-releases/2021/AbCellera… -
AbCellera reposted
SynBioBeta
@SynBioBeta
“It definitely shouldn't be a vaccines vs antibody scenario. There's always going to be a proportion of the population that will not get vaccinated and so, having treatment solutions will still be important,” says Ester Falconer of @AbCelleraBio at #synbiopharma 💉
-
AbCellera
@AbCelleraBio
AbCellera Reports Q1 2021 Business Results investors.abcellera.com/news/news-releases/2021/AbCellera…
-
AbCellera
@AbCelleraBio
Join us at @PEGSboston on May 12 @ 2:30PM EDT to learn about AbCellera’s ongoing #covid-19 response and how we identified bamlanivimab, the first monoclonal antibody therapy for COVID-19 to reach human testing and to be authorized for emergency use by the U.S. FDA. #pegs21
-
AbCellera
@AbCelleraBio
AbCellera to Present Virtually at Berenberg Conference on May 18, 2021 $ABCL investors.abcellera.com/news/news-releases/2021/abcellera…
-
AbCellera
@AbCelleraBio
The AbCellera-discovered antibody LY-CoV1404 may be a long-term complement to COVID-19 vaccines to address SARS-CoV-2 variants. investors.abcellera.com/news/news-releases/2021/New-AbCel…
-
AbCellera
@AbCelleraBio
AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy
investors.abcellera.com/news/news-releases/2021/AbCellera… -
AbCellera
@AbCelleraBio
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
Preprint data shows LY-CoV1404 binds and neutralizes all currently known circulating SARS-CoV-2 variants of concern: investors.abcellera.com/news/news-releases/2021/New-AbCel… -
AbCellera
@AbCelleraBio
AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals investors.abcellera.com/news/news-releases/2021/AbCellera…
-
AbCellera
@AbCelleraBio
AbCellera’s Co-Founder and COO, Veronique Lecault, is featured among some great local business leaders on @readthepeak’s Best of BC list! #betoncanada21
outofontario.readthepeak.com/bc-businesses -
AbCellera
@AbCelleraBio
AbCellera Announces Date of First Quarter 2021 Financial Results Conference Call investors.abcellera.com/news/news-releases/2021/AbCellera…
-
AbCellera
@AbCelleraBio
Congratulations to our CEO Dr. Carl Hansen, who has been named one of the Top 50 Healthcare Technology CEOs of 2021. A big round of applause to all of the awardees for their outstanding leadership and significant contributions in healthcare technology. thehealthcaretechnologyreport.com/the-top-50-healthcare-t…
-
AbCellera
@AbCelleraBio
Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19
investors.abcellera.com/news/news-releases/2021/Published… -
AbCellera
@AbCelleraBio
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
investors.abcellera.com/news/news-releases/2021/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera Reports Full Year 2020 Business Results
investors.abcellera.com/news/news-releases/2021/AbCellera… -
AbCellera
@AbCelleraBio
Opinion: We have antibody therapies for COVID-19: They save lives, now use them
dailyhive.com/vancouver/abcellera-antibody-therapies-opinion -
AbCellera
@AbCelleraBio
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19
investors.abcellera.com/news/news-releases/2021/AbCellera… -
AbCellera
@AbCelleraBio
EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
investors.abcellera.com/news/news-releases/2021/EMA-Advis… -
AbCellera
@AbCelleraBio
"When something seems impossible, take on the challenge and rally."
READ: AbCellera co-founder & COO, Véronique Lecault’s approach to tackling some of biotech’s toughest problems.
#top40under40 financialpost.com/sponsored/business-sponsored/dr-veroniq…
financialpost.com/sponsored/business-sponsored/dr-veroniq… -
AbCellera
@AbCelleraBio
"For every 52 doses administered of monoclonal antibodies with somebody who's tested positive and are high risk, we can save one life." - Dr. David Kessler, chief science officer for the Biden administration's COVID response
www.msnbc.com/rachel-maddow-show/further-information-mono… -
AbCellera
@AbCelleraBio
AbCellera Appoints Ester Falconer, Ph.D. as Chief Technology Officer
www.abcellera.com/news/ester-falconer-appointed-chief-tec… -
AbCellera
@AbCelleraBio
Bamlanivimab is now authorized in two antibody therapy regimens to treat COVID-19 in patients at high risk for hospitalization
www.abcellera.com/news/eua-for-bamlanivimab-and-etesivmab -
AbCellera
@AbCelleraBio
AbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference Call
www.abcellera.com/news/abcellera-announces-date-of-fourth… -
AbCellera
@AbCelleraBio
CEO Carl Hansen talks to @forbes about #abcellera's "white hot IPO" and how improving the process of drug discovery led to the #fda's first emergency use authorization for a monoclonal #antibody to treat #covid19 www.forbes.com/sites/alexknapp/2021/01/26/this-college-pr…
-
AbCellera
@AbCelleraBio
AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19
www.abcellera.com/news/2021-01-27-bamlanivimabs-to-be-dev… -
AbCellera
@AbCelleraBio
The data from the BLAZE-1 study "show that if given early in infection, antibody therapy can keep most patients out of hospitals and can save lives,” -Carl Hansen, CEO AbCellera
www.abcellera.com/news/2021-01-26-bamlanivimab-reduced-ri… -
AbCellera
@AbCelleraBio
Results from @LillyPad's BLAZE-2 trial shows that bamlanivimab significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities
www.abcellera.com/news/2021-01-21-abcellera-discovered-an… -
AbCellera
@AbCelleraBio
AbCellera Granted US Patent Covering its Trianni Mouse® Technology
The Trianni Mouse®, AbCellera’s technology for generating large databases of human antibodies for drug discovery programs, is granted US patent
www.abcellera.com/news/2021-01-19-abcellera-granted-us-pa… -
AbCellera
@AbCelleraBio
adMare Launches Abdera with AbCellera as a Founding Partner
www.abcellera.com/news/2021-01-14-admare-launches-abdera-… -
AbCellera reposted
CNBC's Closing Bell
@CNBCClosingBell
AbCellera’s CEO talks going public and COVID-19 treatments in this #exclusive interview. Watch a clip here:
-
AbCellera
@AbCelleraBio
AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico
www.abcellera.com/news/2020-12-21-abcellera-discovered-ne… -
AbCellera
@AbCelleraBio
AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
www.abcellera.com/news/2020-12-15-abcellera-announces-clo… -
AbCellera
@AbCelleraBio
AbCellera Announces Pricing of Initial Public Offering
www.abcellera.com/news/2020-12-10-abcellera-announces-pri… -
AbCellera
@AbCelleraBio
AbCellera-Discovered Antibody, Bamlanivimab (LY-CoV555), Granted Interim Authorization by Health Canada as a Treatment for #covid19: www.abcellera.com/news/2020-11-20-bamlanivimab-granted-in…
-
AbCellera
@AbCelleraBio
AbCellera and @invetx today announced they have expanded their agreement to generate therapeutic antibody candidates for serious and chronic conditions in animal health: www.abcellera.com/news/2020-11-19-abcellera-invetx-expand…
-
AbCellera
@AbCelleraBio
AbCellera announces the appointment of Peter Thiel to the company's Board of Directors: www.abcellera.com/news/2020-11-19-peter-thiel-joins-board
-
AbCellera
@AbCelleraBio
AbCellera has announced the acquisition of Trianni for $90 million. This expands AbCellera's technology stack with a suite of genetically engineered mice for generating diverse panels of human antibodies with drug-like properties: www.abcellera.com/news/2020-11-18-abcellera-acquires-trianni
-
AbCellera
@AbCelleraBio
AbCellera has announced the appointment of John Montalbano to the company's Board of Directors, and he will serve as the Chair of the Audit Committee: www.abcellera.com/news/2020-11-18-john-montalbano-joins-b…
-
AbCellera
@AbCelleraBio
AbCellera-Discovered Antibody Receives U.S. FDA Emergency Use Authorization as a Monotherapy for the Treatment of COVID-19
www.abcellera.com/news/2020-11-09-bamlanivimab-us-fda-eua -
AbCellera reposted
Eli Lilly and Company
@EliLillyandCo
The @US_FDA has granted emergency use authorization for one of Lilly's neutralizing antibodies to treat mild to moderate #covid19 in high-risk patients. Learn more: e.lilly/35conmQ
-
AbCellera reposted
BC Tech Association
@wearebctech
COO & Co-founder of @AbCelleraBio, Véronique Lecault, accepting the #2020tias Excellence in Global Export award for @AbCelleraBio!
-
AbCellera
@AbCelleraBio
AbCellera is honoured to receive the award for Excellence in Global Export at @wearebctech’s Technology Impact Awards 2020. Congratulations to all of the #2020tias finalists and winners!
www.youtube.com/watch?t=6499&v=A7Oij-7yKtY -
AbCellera
@AbCelleraBio
Congratulations to our Co-founder & Head of Business Development @KHeyries who has been named to @BIVnews Forty Under 40. A tip of the hat to all the award recipients for their outstanding leadership, business excellence, and community contributions.
biv.com/forty-under-40 -
AbCellera
@AbCelleraBio
Congratulations to our Co-founder, Director & COO, Véronique Lecault, for making Canada's Top 40 Under 40. A big thank you to Véronique and her peers for their ingenuity, vision, and leadership. @Top40_40
www.bnnbloomberg.ca/canada-s-top-40-under-40-the-next-lea… -
AbCellera
@AbCelleraBio
Today, AbCellera and @KodiakSciences announced a new partnership to generate therapeutic antibody candidates in ophthalmology. Visit www.abcellera.com/news/2020-10-29-kodiak-second-ab-discov… for more information.
-
AbCellera reposted
GenomeBC
@GenomeBC
1/n Dr. Carl Hansen “…technology has a role to play in responding to incidents like coronavirus &things that happen in the future... as well as the diseases we’re faced on a day to day basis.” He leads tech company @AbCelleraBio which provides solutions to the biotech industry.
-
AbCellera reposted
GenomeBC
@GenomeBC
Don't miss out on registering for our FREE online event on Wednesday!
Our 11th Annual Don Rix Distinguished Keynote Address features Drs. Carl Hansen, Bonnie Henry & Mel Krajden.
Sign up for #drdk2020 here: events.genomebc.ca/drdk2020/673678?ref=SMTWT @AbCelleraBio @CDCofBC -
AbCellera reposted
Eli Lilly and Company
@EliLillyandCo
#breakingnews: Lilly has submitted a request for Emergency Use Authorization for one of our potential #covid19 antibody treatments to @US_FDA. Learn more about the supporting data and progress of our potential combination antibody therapy treatment: e.lilly/33AtuN1
-
AbCellera
@AbCelleraBio
AbCellera is thrilled to be featured as one of the Fierce 15 biotech companies of 2020! Thank you to @FierceBiotech for recognizing us and congratulations to all the companies in this year's impressive line up. #fierce15
www.fiercebiotech.com/special-report/abcellera-fierce-bio… -
AbCellera
@AbCelleraBio
AbCellera and IGM Biosciences, Inc. announced a multi-year, multi-target antibody discovery collaboration to expedite the discovery of novel IgM antibodies.
www.abcellera.com/news/2020-09-24-igm-biosciences-antibod… -
AbCellera
@AbCelleraBio
AbCellera announced that interim data reported for LY-CoV555, the first #covid-19 antibody to emerge from our collaboration with @LillyPad, shows a reduction in the rate of hospitalization in patients treated with the antibody in Phase 2 clinical trials.
www.abcellera.com/news/2020-09-16-interim-data-phase-2-cl… -
AbCellera
@AbCelleraBio
AbCellera announced the acquisition of @dualogics OrthoMab bispecific platform for generating tailored, stable and developable bispecific therapeutics. Computational protein engineering expert, Dr. Tim Jacobs from Dualogics, also joins the team.
More at www.abcellera.com/news/2020-08-20-abcellera-acquires-orth… -
AbCellera
@AbCelleraBio
AbCellera is honoured to be recognized in the 2020 List of Most Innovative Digital Health Startups, showcasing 150 of the most promising private digital health companies across the globe. Thanks @CBinsights for including us in the roundup!
www.cbinsights.com/research/report/digital-health-startup… -
AbCellera
@AbCelleraBio
Great piece in @NatureBiotech exploring how single-cell analysis platforms are reshaping the pandemic drug discovery landscape, including an interview with @AbCelleraBio's CEO, Carl Hansen.
#covid19 #antibodies #drugdiscovery
www.nature.com/articles/s41587-020-0657-2 -
AbCellera
@AbCelleraBio
We are proud to be listed in @businessinsider's 21 biotech companies set to take off in the next year! Special thanks to @DCVCBio for their support & nomination, as well as @lydiaramsey125 for including us in the round up.
www.businessinsider.com/biotech-startups-poised-to-take-o… -
AbCellera
@AbCelleraBio
Exciting news -- @DCVCBio is launching their next $350 million early stage fund to support the next generation of human therapeutics, agriculture and industrial biotech: www.dcvc.com/post/life-sciences-and-deep-tech-the-next-se…
-
AbCellera
@AbCelleraBio
Dan Skovronsky, CSO, @LillyPad was interviewed by @BioProcessIntl on 2 COVID-19 antibody drug programs currently in clinical trials, LY-CoV555 and LY-CoV016. More on how successful COVID-19 monotherapies could help maximize manufacturing capacities:
www.bioprocessintl.com/bioprocess-insider/staying-single-… -
AbCellera
@AbCelleraBio
Today, the @NIH announced plans for ACTIV-2, a clinical trial to test synthetic monoclonal antibodies, including LY-CoV555, along with other experimental therapeutics for mild and moderate COVID-19.
More in the news release: www.niaid.nih.gov/news-events/nih-clinical-trial-test-ant… -
AbCellera reposted
Techtalent.ca
@TechTalentCan
Fast Company Names Four Canadian Workplaces Among Best for Innovators | @Shopify @HighlineBETA @RBCVentures @AbCelleraBio #cdntech #techtalent techtalent.ca/best-workplaces-for-innovators-in-canada/
-
AbCellera reposted
NIH
@NIH
News: NIH launches clinical trial to test antibody treatment in hospitalized COVID-19 patients www.nih.gov/news-events/news-releases/nih-launches-clinic…
-
AbCellera
@AbCelleraBio
AbCellera Provides COVID-19 Program Update with the Start of Phase 3 Clinical Trials and the Expansion of its COVID-19 Antibody Database
investors.abcellera.com/news/news-releases/2020/AbCellera… -
AbCellera reposted
Eli Lilly and Company
@EliLillyandCo
Congratulations, @AbCelleraBio!
AbCellera
@AbCelleraBio
AbCellera has won @FastCompany's Innovative Team of the Year award! In collaboration with Eli Lilly & NIAID’s VRC, the team brought the first COVID-19 antibody to clinical trials in <90 days, a process that typically requires 3-6 years.
www.fastcompany.com/90529857/best-workplaces-for-innovato… -
AbCellera
@AbCelleraBio
We are doubly proud to be recognized in @FastCompany's Best Workplaces for Innovators 2020 as well as the Innovative Team of the Year Award. Together, our bold ideas and collaborative innovation are helping to make the impossible possible.
www.fastcompany.com/90527870/best-workplaces-for-innovato… -
AbCellera
@AbCelleraBio
AbCellera has won @FastCompany's Innovative Team of the Year award! In collaboration with Eli Lilly & NIAID’s VRC, the team brought the first COVID-19 antibody to clinical trials in <90 days, a process that typically requires 3-6 years.
www.fastcompany.com/90529857/best-workplaces-for-innovato… -
AbCellera
@AbCelleraBio
"The speed at which the drug discovery and development process happened—weeks instead of years—indicates “an opportunity to reevaluate how drugs are developed.” - Carl Hansen, Ph.D, AbCellera's Director & CEO.
Read the full story in @NewYorker: www.newyorker.com/science/elements/how-a-potential-treatm… -
AbCellera
@AbCelleraBio
A @NatureMedicine article featured insights from Maia Smith, Lead of Data Visualization at AbCellera: “Mathematical models, statistical approaches, and machine learning are the only way you can make meaning out of so much data." @edbites reports: www.nature.com/articles/d41591-020-00027-9
-
AbCellera
@AbCelleraBio
Today, AbCellera announced an agreement with Alloy Therapeutics, Inc. to integrate access to their ATX-Gx™️ humanized mice platform for antibody discovery programs.
For more information, visit investors.abcellera.com/news/news-releases/2020/AbCellera…. -
AbCellera
@AbCelleraBio
Our partner @invetx has announced the launch of its platform for discovering novel medicines for the animal health market, which combines state-of-the-art technologies from partners @AbCelleraBio, @TwistBioscience & WuXi Biologics.
www.invetx.com/invetx-announces-industry-leading-antibody… -
AbCellera reposted
Julia Chatterley
@chattwithjulia
“It is both an advanced guard and also a reinforcement to the body’s own immune response.” @AbCelleraBio CEO Carl Hansen is working with $LLY to develop #antibody treatments, saying their #covid19 drug “could be available THIS year.”
This media couldn't be displayed. See it on the original post. -
AbCellera
@AbCelleraBio
AbCellera's Director & COO, Véronique Lecault, PhD, was recently featured in @TheTyee's story "The Vancouver Company Turning Blood into a COVID Treatment".
More on the life-saving potential of antibody therapies in the video: thetyee.ca/News/2020/07/01/Vancouver-Company-Covid-Blood-… #covid19 #antibodydrugs -
AbCellera
@AbCelleraBio
Join today's AWS Healthcare & Life Sciences Web Day, featuring a fantastic lineup of industry experts, including our CEO, Carl Hansen. Hear expert insights on how technology is accelerating the global health crisis response.
aws.amazon.com/events/
#awshealthcare -
AbCellera
@AbCelleraBio
Join our free virtual event to hear our CEO, Carl Hansen, give a keynote address on how we identified a potential drug candidate for COVID-19 in under four months. aws.amazon.com/events/ #awshealthcare
-
AbCellera
@AbCelleraBio
AbCellera’s antibody discovery engines are leading the search for antibodies against SARS-CoV-2 with unprecedented throughput and speed.
More on AbCellera’s journey from patient sample to lead antibody in our COVID-19 response infographic: www.abcellera.com/post/2020-07-06-abcellera-covid19-respo… #covid19 -
AbCellera
@AbCelleraBio
AbCellera and other groups are developing technologies such as DNA-encoded antibodies that can drastically reduce response times in the event of viral disease outbreaks.
More in this article from @techreview:
www.technologyreview.com/2020/06/18/1004024/treatments-dn…
#covid19 #pandemic -
AbCellera
@AbCelleraBio
AbCellera is looking forward to attending
@BIOConvention 2020! Get in touch with us and find out how our antibody discovery platform can get your biologic to the clinic faster. #biodigital -
AbCellera
@AbCelleraBio
Thanks @RLCscienceboss for the in-depth coverage, and thanks to @cenmag for featuring this article as part of your COVID-19 coverage. #covid19
Ryan Cross the Science Boss
@RLCscienceboss
In some good news, @lillypad $LLY has begun a Phase I clinical trial of an anti-#sarscov2 monoclonal #antibody discovered by @AbCelleraBio more than a month ahead of schedule. Discovery to injection time was a (likely) record-setting 90 days. @cenmag cen.acs.org/pharmaceuticals/drug-development/Lilly-begins…
-
AbCellera
@AbCelleraBio
Our partner @LillyPad announced that our lead #antibody candidate has entered clinical trials for the potential treatment of #covid19. Thank you to our teams and partners who have worked tirelessly to go from patient sample to clinical trial in 3 months.
investor.lilly.com/news-releases/news-release-details/lil… -
AbCellera
@AbCelleraBio
AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment.
www.abcellera.com/news/2020-06-01-worlds-first-covid-19-c…
#antibody #covid19 #drugdiscovery -
AbCellera reposted
Matthew Herper
@matthewherper
Eli Lilly begins first human tests of an antibody drug against Covid-19. $LLY
Others, including $REGN and $VIR, are expected to begin studies soon.
"We’re racing against the death toll from the virus," says $LLY CSO.
www.statnews.com/2020/06/01/eli-lilly-begins-first-human-… -
AbCellera
@AbCelleraBio
AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery Platform
investors.abcellera.com/news/news-releases/2020/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera announces multi-year, multi-target strategic research collaboration and license agreement with @LillyPad for novel antibody therapeutics: www.abcellera.com/news/20-05-22-lilly-multitarget-collabo…
-
AbCellera
@AbCelleraBio
AbCellera's Véronique Lecault (Director & COO) featured in an interview on @cbcradio's Les Années Lumière. Listen to the full segment "Les anticorps monoclonaux pour combattre la COVID-19" here: ici.radio-canada.ca/ohdio/premiere/emissions/les-annees-l… #covid19
-
AbCellera
@AbCelleraBio
AbCellera's technology and our teams' efforts to find potent antibodies targeting SARS-CoV-2 have been featured in this article by @emilylmullin for @ozm: onezero.medium.com/the-race-is-on-to-find-the-holy-grail-… #covid19
-
AbCellera
@AbCelleraBio
Today, PM Trudeau and Minister Bains announced AbCellera's project with the Strategic Innovation Fund (SIF). We are proud to have the support of the Government of Canada to combat COVID-19 & help build Canadian capabilities to fight future pandemics.
investors.abcellera.com/news/news-releases/2020/AbCellera… -
AbCellera
@AbCelleraBio
AbCellera's Celium™ has been featured on @biospace! Celium™ is the first interactive software that lets scientists intuitively explore antibodies like never before and pick antibodies with the greatest chance of becoming successful drugs. www.biospace.com/abcellera-and-lilly-slash-antibody-selec… #covid19
-
AbCellera
@AbCelleraBio
AbCellera is honoured to be selected amongst an amazing group of homegrown #bctech companies for a #2020tias award. Thank you to @wearebctech for the nomination and congrats to all of our fellow nominees!
-
AbCellera
@AbCelleraBio
“We always hope there’s just one antibody that’s really, really great, and we can devote our full manufacturing resources to that.” - Dan Skovronsky, CSO, @LillyPad. Our partnership to develop #covid19 antibody drugs featured in an article by @BW: www.bloomberg.com/news/features/2020-04-20/antibody-treat…
-
AbCellera
@AbCelleraBio
AbCellera's CFO, Andrew Booth speaks with @VanEconomic about innovation, connectedness and the public’s role in rising above the COVID-19 crisis:
www.vancouvereconomic.com/blog/news/abcellera-biologics-d… #covid19 -
AbCellera
@AbCelleraBio
Within 3 days, AbCellera had inspected 5 million cells and found 500 different antibodies that stuck to the “spike” protein of the virus, potentially blocking it. Any one of these antibodies could be a cure for others infected. @techreview #covid19 www.technologyreview.com/2020/04/10/998897/the-race-to-ma…
-
AbCellera reposted
SynBioBeta
@SynBioBeta
Join our #covid19 #antibodies roundtable with Carl Hansen of @AbCelleraBio, @Eric_D_Hobbs of @berkeley_lights, @aaronksato of @TwistBioscience, James Crowe of @VUMC_Vaccines, and @CurlyJungleJake of @distributedbio, Friday at 8 am PDT go.synbiobeta.com/l/408192/2020-04-13/ljc8vz #coronavirus
-
AbCellera
@AbCelleraBio
“It’s a therapy that skips over the vaccine process altogether,” says AbCellera's CEO, Carl Hansen. “It’s a precision medicine that will work for everyone and works more quickly.”
More as @nafeesakarim reports for @CTV: bc.ctvnews.ca/human-testing-for-vancouver-developed-covid… -
AbCellera
@AbCelleraBio
All of us at AbCellera echo our CEO, Carl Hansen's gratitude to everyone helping our communities rise above the COVID-19 crisis.
Whether you're working on the frontlines, supporting essential services or doing your part by staying home - we thank you.
www.linkedin.com/posts/carl-hansen-19451276_as-abcellera-… -
AbCellera reposted
Nafeesa Karim
@nafeesakarim
The story I’m on tonight for @CTVVancouver is buoying me during this gloom. Vancouver-based @AbCelleraBio is developing antibody treatments for #covid19. Human testing could start by July. CEO Carl Hansen, a former @UBC prof told me, “it’s absolutely the case that there is hope.”
-
AbCellera reposted
Nafeesa Karim
@nafeesakarim
Here’s what I worked on today for @ctvvancouver. I’m feeling hopeful after having done this interview today with the CEO of @AbCelleraBio. Human testing for Vancouver-developed COVID-19 antibody drug could start by July bc.ctvnews.ca/human-testing-for-vancouver-developed-covid…
-
AbCellera
@AbCelleraBio
As Ted Chernecki reports for @globalnews, Abcellera is hoping to start clinical trials for a potent, well-defined antibody-based COVID-19 treatment in just a few months, in partnership with @LillyPad.
globalnews.ca/video/6792253/b-c-biotech-company-working-o… -
AbCellera
@AbCelleraBio
AbCellera's CEO, Carl Hansen interviewed by @BNNBloomberg about AbCellera's ongoing efforts to develop antiviral treatments against COVID-19. www.bnnbloomberg.ca/video/~1935556
-
AbCellera
@AbCelleraBio
Don't miss @CDCofBC & @UBC's Virtual BC COVID-19 Symposium on Thursday via Zoom. Our Scientific Director, Bo Barnhart, will be presenting on @AbCelleraBio's involvement in the pandemic response. www.med.ubc.ca/research-2/virtual-bc-covid-19-symposium/
-
AbCellera
@AbCelleraBio
AbCellera is mentioned in
@CNN_newstrend's overview of the COVID-19 drug development landscape: eturbonews.com/treatment-and-vaccination-a-european-covid… -
AbCellera
@AbCelleraBio
Exciting to se AbCellera featured alongside other innovative @ubcentrepreneur ventures that are stepping up to respond to the COVID-19 emergency. innovation.ubc.ca/post/venture-spotlight-series-the-game-…
-
AbCellera
@AbCelleraBio
Proud to be mentioned in @GTaccelerator's roundup of innovative Canadian companies working full throttle towards a COVID-19 response.
medium.com/@info_40215/five-canadian-companies-that-are-h… -
AbCellera
@AbCelleraBio
"Across the industry... everybody is working around the clock, and I think at lightning speed and in ways we never have before." - David Ricks, CEO, Eli Lilly. AbCellera & Lilly are rapidly moving forward with the development of COVID-19 countermeasures: www.foxbusiness.com/markets/eli-lilly-developing-potentia…
-
AbCellera
@AbCelleraBio
"AbCellera's platform has delivered, with unprecedented speed, by far the world's largest panel of anti-SAR-CoV-2 antibodies." - Carl Hansen, CEO. More at: www.abcellera.com/news/2020-03-abcellera-and-lilly-codeve…
-
AbCellera
@AbCelleraBio
Nice roundup of global efforts to develop preventative measures and therapeutics to combat COVID-19: www.fiercebiotech.com/biotech/biopharma-s-leading-treatme…
-
AbCellera reposted
Joyce Murray
@JoyceMurray
Canada is fighting back against #covid19. The government has committed $275 million for coronavirus research, including the development of vaccines.
One of those projects, done by @AbCelleraBio, is being done right here in Vancouver.
More here: pm.gc.ca/en/news/news-releases/2020/03/23/canadas-plan-mo… -
AbCellera
@AbCelleraBio
Using machine learning, AbCellera can recognize patterns in antibodies to find the ones that show the most promise in fighting off the coronavirus www.wsj.com/articles/biotech-company-uses-machine-learnin… via @WSJ
-
AbCellera reposted
DARPA
@DARPA
As part of our P3 program, @AbCelleraBio and @VUMChealth obtained the first SARS-CoV-2 immune cells and initiated studies to identify antibodies. 700 antibody targets were identified by AbCellera, which is working w/ Eli Lilly to accelerate products for treatment and prevention.
-
AbCellera
@AbCelleraBio
We've been featured in a recent @NatureBiotech article exploring the milestones and challenges in the current #covid19 drug development landscape. For full coverage, including an interview with Ester Falconer, @AbCelleraBio's Head of R&D: idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nat…
-
AbCellera
@AbCelleraBio
Today, @JustinTrudeau announced that the Canadian Govt will spend $192M on developing COVID-19 vaccine & treatments. @AbCelleraBio is deeply honored to receive this support for our efforts in discovering & developing an antibody treatment for COVID-19.
youtu.be/Xz5GUbGL69k -
AbCellera
@AbCelleraBio
“There are scientific reasons why it may not work, but there are also scientific reasons why it may work, and that's absolutely the right place for DARPA to be investing.” Amy Jenkins, program manager @DARPA.
www.biocentury.com/article/304691/darpa-jump-started-tech… -
AbCellera
@AbCelleraBio
Within a week of receiving a blood sample from a patient who recovered from #covid19, AbCellera identified 500 human antibodies against SARS-CoV-2, the largest antibody panel reported to date. For more, click here for @GENbio's article: www.genengnews.com/news/to-develop-coronavirus-treatment-…
-
AbCellera reposted
Andrew Dunn
@AndrewE_Dunn
"We've never moved at this speed before. I'm not sure any company ever has, but I think if there's one situation that demands speed and demands extraordinary effort, it's the COVID-19 pandemic," Eli Lilly chief scientific officer Dan Skovronsky told me.
www.businessinsider.com/eli-lilly-abcellera-plan-to-devel… -
AbCellera
@AbCelleraBio
@AbCelleraBio and @LillyPad to Co-develop Antibody Therapies for the Treatment of COVID-19: www.abcellera.com/news/2020-03-abcellera-and-lilly-codeve…
-
AbCellera
@AbCelleraBio
We’re honoured to have earned a spot on @FastCompany’s Most Innovative Companies of 2020 list for our antibody discovery platform that’s bringing better treatments to patients, faster. #fcmostinnovative
www.abcellera.com/news/2020-02-mostinnovativecompanies2020 -
AbCellera
@AbCelleraBio
AbCellera is mobilizing to respond to the Wuhan coronavirus outbreak as part of the DARPA P3 program.
#abcellera #antibodytherapeutic #wuhan #wuhancoronavirus #coronavirus #2019ncov #antibody #singlecell -
AbCellera
@AbCelleraBio
How to select the best therapeutic candidates when you have hundreds of antibody sequences? Celium, our custom visualization software, helps partners navigate rich datasets to select their favorite leads. See how: youtu.be/d7bPP-ynSJ4
#antibodydiscovery #datavisualization -
AbCellera
@AbCelleraBio
Check out our new website! Find out more about the expertise and technologies behind AbCellera's therapeutic antibody discovery engine. www.abcellera.com/discovery
#antibodydiscovery #singlecell #repseq #ai #bigdata -
AbCellera
@AbCelleraBio
AbCellera announces patents on the use of microfluidics for high-throughput single-cell assays that extend protection of its market-leading technology in antibody discovery and clone selection.
investors.abcellera.com/news/news-releases/2019/AbCellera…
#singlecell #antibodydiscovery -
AbCellera
@AbCelleraBio
We’re excited to announce that Michael Hayden, a successful entrepreneur and translational scientist, has joined AbCellera’s board of directors. Welcome Dr. Hayden!
www.abcellera.com/news/2019-10-michael-hayden-joins-board
#antibodydiscovery #antibodies #singlecell -
AbCellera
@AbCelleraBio
Lead Celium(TM) Developer, Maia Smith, speaks at @SynBioBeta today at 1:30pm on the Main Stage. Learn how Celium(TM) helps AbCellera’s scientists and partners choose lead therapeutic candidates from hundreds of diverse antibody sequences. Read more here: synbiobeta.com/plugging-into-the-immunology-matrix/
-
AbCellera
@AbCelleraBio
AbCellera has been working hard, and it shows! AbCellera ranked Canada’s fastest growing biotech and one of Vancouver’s top 10 fastest growing companies among Canada’s Top Growing Companies. www.abcellera.com/news/2019-09-canadas-top-growing-companies
#vancouver #biotech #topgrowing19 -
AbCellera
@AbCelleraBio
AbCellera appoints Andrew Booth as Chief Financial Officer and Tryn Stimart as General Counsel. With their added leadership in finance, intellectual property, and strategy, AbCellera is set for rapid growth. www.abcellera.com/news/2019-09-abcellera-appoints-cfo-and… #singlecell #antibodydiscovery #bigdata
-
AbCellera
@AbCelleraBio
AbCellera was named Company of the Year - Scale Success at Technology Impact Awards! #2019tias We are proud to be nominated among BC's innovators, developing tech to solve therapeutic problems. Join us! www.abcellera.com/careers
-
AbCellera
@AbCelleraBio
AbCellera announced today that it has entered into an agreement with Gilead Sciences to support the discovery of therapeutic antibody candidates for infectious diseases. #singlecell #antibodydiscovery #infectiousdisease www.abcellera.com/news/2019-06-abcellera-antibody-discove…
-
AbCellera
@AbCelleraBio
At AbCellera, we choose to work with people who are passionate, intelligent, and team players. Those guiding values just happen to have created a diverse and balanced team. Congratulations to all those whose hard work and contributions were recognized by @BMO.
BMO
@BMO
Congratulations to @IntegraResource’s Andrée St-Germain, @nanasauce’s Shelina Mawani, @AbCelleraBio’s Véronique Lecault and @GroYourBiz’s Barbara Mowat, who we honoured last week at our BMO Celebrating Women event in Vancouver #bmoforwomen.
-
AbCellera
@AbCelleraBio
AbCellera completes the @FB_Canada @CycleforSight fundraising ride after logging 1961.27 km in the @WeAreHub #bike2work Week! #vancouver #everydayimcycling
-
AbCellera
@AbCelleraBio
AbCellera announces partnership with #niaid Vaccine Research Center and #ichormedical Systems to develop a nucleic acid encoded #antibody countermeasure against pandemic #influenza.
www.abcellera.com/news/2019-05-abcellera-p3-partnership-w…
#singlecell #antibodydiscovery -
AbCellera
@AbCelleraBio
Learn how AbCellera is using its #antibodydiscovery technology to develop a rapid #pandemic response platform. Join us at the World Vaccine Congress in Washington. www.terrapinn.com/conference/world-vaccine-congress-washi…
#singlecell #infectiousdisease #preparedness -
AbCellera
@AbCelleraBio
Hate the idea of a desk job? Want to do something amazing in science? We're hiring technicians in cell culture, molecular biology and expression, and sequencing!
www.abcellera.com/careers/WrpnjCsAACwAQVb5?platform=hoots…
#lifesciences #antibody #vancouverjobs -
AbCellera
@AbCelleraBio
AbCellera's Dr Kevin Heyries and Caitlin Webster will be speaking at @TheSBN Biotech Expo tomorrow. Find out about interesting careers in science and what it's like to start a biotech company in #vancouver
www.eventbrite.ca/e/the-sbn-biotech-expo-conference-ticke… -
AbCellera
@AbCelleraBio
We're hiring #software developers! www.abcellera.com/careers/XJJyIxIAACYAWhCB?platform=hoots…
#programmer #vancouver #jobs #jobopening -
AbCellera
@AbCelleraBio
AbCellera is going to be at #womenhackvancouver. Find out how we're building complex data visualization and analysis tools, leveraging rich antibody datasets and machine learning. Don't know what an #antibody is? Ask us!
www.eventbrite.com/e/womenhack-vancouver-employer-ticket-…
#vancouver #womenintech #tech -
AbCellera
@AbCelleraBio
The collaborations funded under the present agreement will benefit from AbCellera’s new technology capabilities for deep profiling of antibody responses.
www.abcellera.com/news/2019-03-abcellera-signs-agreement-…
#antibodies #singlecell #antibodydiscovery #infectiousdisease #drugdiscovery #vaccines -
AbCellera
@AbCelleraBio
AbCellera today announced a two-year agreement with the @gatesfoundation to help accelerate global health research.
www.abcellera.com/news/2019-03-abcellera-signs-agreement-…
#antibodies #singlecell #antibodydiscovery #infectiousdisease #drugdiscovery #vaccines -
AbCellera
@AbCelleraBio
Our very own Veronique Lecault will be presenting "Antibody revolution and technology evolution" in Rm 2311 tomorrow at #big19reseachday. We're looking forward to a BIG day of research!
www.bigresearchday.com/concurrent-sessions-i?platform=hoo… -
AbCellera reposted
Michael Smith Labs
@ubcmsl
Did you know that @AbCelleraBio's core technology came from research out of #ubcmsl? Read how a @ubcscience research group spun-out to become an industry-leading #biotech company! www.msl.ubc.ca/msl-research-group-spins-out-an-industry-l… @techtransfer @UBCphas
-
AbCellera
@AbCelleraBio
We're doing amazing research and pushing the limits of science. Join us!
We're hiring scientists into our Cell Screening, Molecular Biology, and Expression teams. www.abcellera.com/careers/Wrpo8CsAACwAQVxS?platform=hoots…
#lifesciences #antibodies #vancouver #jobs -
AbCellera
@AbCelleraBio
AbCellera Co-Founder Kevin Heyries will be talking about antibody discovery campaigns against challenging membrane protein targets at the American Antibody Congress. See you in San Diego!
www.terrapinn.com/conference/festival-of-biologics-usa/ag…
#antibodies #singlecell #antibodydiscovery -
AbCellera
@AbCelleraBio
AbCellera and Denali expand collaboration to find antibodies against neurological diseases #antibodies #singlecell #antibodydiscovery #defeatdegeneration
www.abcellera.com/news/2019-02-abcellera-denali-sign-mult… -
AbCellera
@AbCelleraBio
With expanded multi-year, multi-target deal, Abcellera and Denali Therapeutics Inc. will work to find new biologics for neurodegenerative diseases www.abcellera.com/news/2019-02-abcellera-denali-sign-mult…
#antibodies #singlecell #antibodydiscovery #defeatdegeneration -
AbCellera reposted
Genetic Engineering & Biotechnology News
@GENbio
. @Novartis Creates “Inflection Point” for @AbCelleraBio with 10-Target Antibody Collaboration: www.genengnews.com/news/novartis-creates-inflection-point…
-
AbCellera reposted
FierceBiotech
@FierceBiotech
Novartis will make upfront payments, fund research and, depending on the success of the programs, hand over milestones and royalties: www.fiercebiotech.com/biotech/novartis-inks-10-target-ant… $NVS
-
AbCellera
@AbCelleraBio
AbCellera today announced a multi-target and multi-year collaboration with @Novartis for therapeutic #antibodydiscovery www.abcellera.com/news/2019-02-abcellera-announces-multi-…
#singlecell #ai -
AbCellera
@AbCelleraBio
Check it out! @AbCelleraBio Group Leader Ester Falconer is about to give a talk at #ptk19 room Aqua D: Combining high-throughput single-B cell screening with Ig-Seq for comprehensive analysis of natural immune responses.
www.chi-peptalk.com/antibody-discovery/?platform=hootsuite
#antibodies #drugdiscovery #repseq -
AbCellera reposted
Andrew Booth
@andrewjsbooth
Exciting to see @AbCelleraBio on @BiotechFocus' list of top five Canadian biotech private venture capital financings in 2017-18. www.biotechnologyfocus.ca
Congratulations to all those helping to build Canada's biotech community! -
AbCellera
@AbCelleraBio
.@AbCelleraBio is at #ptk19! We’re presenting results of combining repertoire sequencing of natural immune responses with functional annotation of antibody sequences Jan 17 @ 9:30. Or find us at the poster session.
www.chi-peptalk.com/antibody-discovery/?platform=hootsuite
#antibodies #drugdiscovery #repseq -
AbCellera
@AbCelleraBio
.@AbCelleraBio Group Leader Sherie Duncan is about to give a talk @AntibodyEng365: Combining High-Throughput Single-Cell Screening with Ig-Seq: Deep Screening and Functional Annotation of Human Antibody Repertoires.
#antibodies #drugdiscovery #biologics #antibodytherapeutics -
AbCellera
@AbCelleraBio
AbCellera is going to Antibody Engineering & Therapeutics! We will be presenting a talk Dec 12 @ 7:30 AM. See you in San Diego @AntibodyEng365
#antibodies #drugdiscovery #biotechnology #antibodytherapeutics
informaconnect.com/antibody-engineering-therapeutics/?pla… -
AbCellera
@AbCelleraBio
Your work makes a human impact, you solve tough problems with a collaborative team, and we're growing - interested in a career here?
Lab manager, software developers, lab technicians, and scientists.
www.abcellera.com/careers?platform=hootsuite
#biotechnology #antibody #sciencejob #softwarejob -
AbCellera
@AbCelleraBio
AbCellera collaborates with Autolus on antibody discovery project. AbCellera will isolate novel antibodies for the development of targeted CAR-T cell therapy.
#biotechnology #antibodies #tcelltherapies www.abcellera.com/news/2018-11-abcellera-collaborates-wit… -
AbCellera
@AbCelleraBio
.@AbCelleraBio co-founder, Véronique Lecault, is about to present at #pegseurope. You can find our talk under in the Engineering Antibodies conference stream.
#antibodies #drugdiscovery #biologics #biotechnology -
AbCellera
@AbCelleraBio
AbCellera is going to PEGS Europe! Our co-founder, Véronique Lecault, will be giving a talk Nov 14 @ 13:45. Hope you can make it. See you in Lisbon!
#antibodies #drugdiscovery #biotechnology -
AbCellera reposted
Life Sciences BC
@lifesciences_bc
Upcoming @McCarthy_ca Spotlight Speaking Series will focus on "The Science of Communication" on November 8 at 4pm. Speakers from @PR_Associates @innovate_bc @AbCelleraBio & Cube Business Media. Tickets: lifesciencesbc.ca/event/lifesciences-bc-mccarthy-spotligh… #lsbcevents #communications #vancouver
-
AbCellera
@AbCelleraBio
At 12:00 today, Dr Kevin Heyries from @abcellerabio will discuss how to overcome immune tolerance to find antibodies against highly conserved therapeutic targets.
#antibodies #drugdiscovery #festivalofbiologics -
AbCellera
@AbCelleraBio
.@AbCelleraBio is at the #festivalofbiologics! Oct 31st @ 12:00PM. Dr Kevin Heyries will discuss how deep mining of natural immune repertoires can overcome immune tolerance to find antibodies against highly conserved therapeutic targets.
#antibodies #drugdiscovery -
AbCellera reposted
Maria Bernabeu
@marietabernabeu
How to fight a pandemic? @AbCelleraBio can screen antibodies from sick people/animals in 5 days to quickly respond to infections such as ebola or flu #singlecell2018 @CIDResearch
-
AbCellera reposted
hackseq
@hackseq
#hackseq18 is underway! Amazing to see so many creative #bioinformatics projects being hacked together!
Thx to our sponsors for helping make this happen: @ecoscope_ubc @GenomeBC @msfhr @AbCelleraBio @rstudio @Bioinfodotca -
AbCellera reposted
Science in Vancouver
@ScienceVancity
Congratulations to @AbCelleraBio on the official opening of their new facility in Cambie village! It's always great to see a Vancouver-based life science company that is not only thriving, but has employees that are so clearly passionate about what they do! @KHeyries
-
AbCellera
@AbCelleraBio
AbCellera celebrates opening of new research facility and corporate headquarters in the heart of Vancouver
#antibodies #ai #ml #biotech #vancouver #drugdiscovery www.abcellera.com/news/2018-10-18-abcellera-celebrates-op… -
AbCellera
@AbCelleraBio
.@AbCelleraBio closes Series A lead by @DVCVBio, a deep tech life science venture capital fund within @DCVC. Financing will build capacity in #ai, protein engineering, immune repertoire profiling. www.abcellera.com/news/2018-09-abcellera-closes-series-a-…
-
AbCellera
@AbCelleraBio
.@AbCelleraBio closes Series A led by @DCVCBio, welcomes John Hamer and Véronique Lecault to the Board of Directors www.abcellera.com/news/2018-09-abcellera-closes-series-a-…
-
AbCellera reposted
SBN
@TheSBN
We are pleased to host @AbCelleraBio's Véronique Lecault (Co-founder & Corporate Development) as a panel speaker at this year's Building Biotech. Secure your tix at Early Bird prices by Sept 10: thesbn.ca/Events/2018-19/building-biotech-2018
-
AbCellera
@AbCelleraBio
AbCellera is presenting at Discovery on Target! You can find us under the Antibodies Against Membrane Protein Targets stream: Sept 26 @ 2:55 and Sept 27 @ 3:55
-
AbCellera reposted
GenomeBC
@GenomeBC
Health news for BC! @AbCelleraBio is partnering with @UBC to discover, test, and develop therapeutic antibodies for the treatment of Duchenne Muscular Dystrophy-associated fibrosis. www.genomebc.ca/fight-against-duchenne-muscular-dystrophy… @ubclifesciences @ubcscience @ubcmsl @GenomeCanada
-
AbCellera reposted
Michael Smith Labs
@ubcmsl
.@AbCelleraBio, a spin-off built on the research done at @ubcmsl, received $3M in funding from @GenomeBC & @GenomeCanada (as part of the Genomics Application Partnership Program) for a $6.5M project for Duchenne Muscular Dystrophy (DMD) research
AbCellera
@AbCelleraBio
.@AbCelleraBio and UBC secure $6.5 million project to fight #duchenne #musculardystrophy
@genomeBC @GenomeCanada @ubcmsl @UBCscience #antibodydiscovery #biotech #dmd
www.abcellera.com/news/2018-08-fight-against-duchenne-mus… -
AbCellera
@AbCelleraBio
.@AbCelleraBio and UBC secure $6.5 million project to fight #duchenne #musculardystrophy
@genomeBC @GenomeCanada @ubcmsl @UBCscience #antibodydiscovery #biotech #dmd
www.abcellera.com/news/2018-08-fight-against-duchenne-mus… -
AbCellera
@AbCelleraBio
Check out our own Dr. Kevin Heyries at TEDx Vancouver on Sept 8!
#therapeuticantibodies #tedxvancouver #biotech -
AbCellera
@AbCelleraBio
.@AbCelleraBio captures foundational #antibody repertoire sequencing technology for immune profiling with acquisition of Lineage Biosciences
www.abcellera.com/news/2018-07-abcellera-acquires-lineage…
#antibodydiscovery #biotech #biotechnews #pharma #pharmanews -
AbCellera
@AbCelleraBio
@AbCelleraBio announces successful first phase of collaboration with $DNLI for the discovery of therapeutic monoclonal #antibodies against #neurodegenerative diseases. www.abcellera.com/news/2018-06-abcellera-announces-collab… #biotech #biologics #antibodydiscovery
-
AbCellera
@AbCelleraBio
@AbCelleraBio & @Harbour_Ab announce technology co-offering agreement for next-generation fully-human #antibody discovery
www.abcellera.com/news/2018-05-abcellera-and-harbour-anti… #mabs #biologics #antibodydiscovery #singlecell -
AbCellera
@AbCelleraBio
AbCellera Biologics awarded multi-year contract from @DARPA to develop rapid response platform against pandemic viral threats. www.abcellera.com/news/18-03-abcellera-awarded-multi-year…
www.darpa.mil/news-events/2018-02-22
#biotech #antibody #singlecell #darpa #antibodydiscovery -
AbCellera
@AbCelleraBio
It’s International Women’s Day today! At @AbCelleraBio, we are proud to have a majority of women working/leading/solving some of the most complex challenges in antibody discovery.
www.internationalwomensday.com #iwd2018 #internationalwomensday -
AbCellera
@AbCelleraBio
AbCellera awarded Growth Stage Company of the Year by @lifesciences_bc
#bcbiotech #antibody #singlecell #antibodydiscovery www.abcellera.com/news/abcellera-named-lsbc-growth-stage-… -
AbCellera
@AbCelleraBio
Announcing the launch of our 25th partnered discovery program! #bcbiotech #antibody #singlecell #antibodydiscovery www.abcellera.com/news/2018-01-abcellera-announces-25th-p…
-
AbCellera
@AbCelleraBio
We excited to announce that the new AbCellera website is now live! Check it out at www.abcellera.com #biotech #abcellera
-
AbCellera
@AbCelleraBio
Excited to announce that we are joining forces with @GSK on a new antibody discovery collaboration!
www.abcellera.com/_news/abcellera-launches-antibody-disco… -
AbCellera
@AbCelleraBio
Excited to announce a new therapeutic #antibodydiscovery collaboration with @tevapharm #biotech www.abcellera.com/_news/20170613
-
AbCellera
@AbCelleraBio
Excited to announce that we are collaborating with @sanofi to research & develop next generation influenza vaccines globenewswire.com/news-release/2017/06/06/1008638/0/en/Ab…
-
AbCellera
@AbCelleraBio
AbCellera named as 1 of 12 cutting-edge BC Companies to receive Govt of Canada funding via the WINN Initiative www.marketwired.com/press-release/-2203171.htm
-
AbCellera
@AbCelleraBio
AbCellera named by @VancouverSun as one of BC's fast growing Biotech Companies! vancouversun.com/business/local-business/b-c-s-biotech-le…
-
AbCellera
@AbCelleraBio
#abcellera receives grant from @gatesfoundation to fund discovery of TB #antibodies. www.abcellera.com/_news/20170119-Gates-Foundation #biotech #gatesfoundation
-
AbCellera
@AbCelleraBio
Excited to announce a multi-year collaboration with @pfizer to discover #antibodies against membrane targets www.abcellera.com/_news/20170105-Pfizer
-
AbCellera
@AbCelleraBio
AbCellera is heading to San Diego to Present at IBCs #antibody & Engineering Conference (Dec 11-15) More Info Here -www.abcellera.com/news
-
AbCellera
@AbCelleraBio
#abcellera screens 1M+ antibody-producing cells; delivers relevant sequences for Kodiak www.abcellera.com/_news/20160824-kodiak
-
AbCellera
@AbCelleraBio
Platform leverages benefits of in vivo selection & maturation; avoids inefficiency of traditional approaches www.abcellera.com/_news/20160824-kodiak
-
AbCellera
@AbCelleraBio
“AbCellera has outperformed our expectations” says CEO Kodiak Science about our #antibody discovery work www.abcellera.com/_news/20160824-kodiak
-
AbCellera
@AbCelleraBio
AbCellera Completes Antibody Discovery Project with Kodiak Sciences to Identify Lead Therapeutic Candidate www.abcellera.com/_news/20160824-kodiak
-
AbCellera
@AbCelleraBio
#abcellera & @MassBiologics partner to tackle hospital-acquired infections in new @DARPA funded project www.abcellera.com/_news/2016-07-20-MassBiologics
-
AbCellera
@AbCelleraBio
AbCellera &@MassBiologics Partner to Discover Fully Human Antibodies Against Drug-Resistant Bacteria www.abcellera.com/_news/2016-07-20-MassBiologics
-
AbCellera
@AbCelleraBio
AbCellera Named to 2016 Life Science Emerging Rockets List of High Growth Companies by @readytorocket #r2r www.abcellera.com/_news/2016-03-02-readytorocket2016
-
AbCellera
@AbCelleraBio
Aequus named Growth Stage Life Sciences Company of the Year by @lifesciences_bc.Congrats to the team, including our chairman, Doug Janzen.
-
AbCellera
@AbCelleraBio
Carl Hansen, Phd, Founder & CEO of AbCellera, will be speaking about Bioengineering at Biotech Expo. thesbn.ca/Events/2015-16/biotech-expo-2016 RT @TheSBN
-
AbCellera
@AbCelleraBio
CDRD spin-out companies heading to @theC100 #doseofthevalley in #sanfrancisco next week! admarebio.com/en/ #startup RT @C_D_R_D
-
AbCellera
@AbCelleraBio
Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies www.abcellera.com/_news/2016-02-02-teva #biotech #drugdiscovery
-
AbCellera
@AbCelleraBio
AbCellera & Merck Sign Novel Therapeutic Antibody Discovery Collaboration www.abcellera.com/_news/2016-01-27-merck #antibodydiscovery #drugdiscovery
-
AbCellera
@AbCelleraBio
Veronique Lecault steps up at 12pm to talk about accessing #antibody diversity by deep screening plasma cell compartments #ptk16
-
AbCellera
@AbCelleraBio
Our partnership w/ @massbiologics to discover human #antibodies against #ecoli & #ebola, funded by @darpa www.abcellera.com/_news/2016-01-20-MassBiologics_DARPA



























































































































































































































































































